Коронарные интервенции у больных с сахарным диабетом II типа: эффективность и безопасность
Download
2. Gruеntzig A. R., Senning A., Siegenthaler W. E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty // N. Engl. J. Med. – 1979. – Vol. 301. – P. 61–68.
3. Hammound T., Tanguay J. F., Bourassa M. G. Management of coronary artery disease: therapeutic options in patients with diabetes // J. Amer. Coll. Cardiol. – 2000. – Vol. 36. – P. 355–365.
4. King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995 – 2025: prevalence, numerical estimates, and projections // Diabetes Care. – 1998. – Vol. 21. – P. 1414–1431.
5. Smith S. C., Faxon D., Cascio W. et al. Diabetes and cardiovascular disease writing group VI: revascularization in diabetic patients // Circulation. – 2002. – Vol. 105. – P. e165–e169.
6. Flaherty James D., Davidson Charles J. Diabetes and Coronary Revascularization // JAMA. – 2005. – Vol. 293. – P. 1501–1508.
7. Mak K. H., Moliterno D. J., Granger C. B. et al. GUSTO-I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction // J. Amer. Coll. Cardiol. – 1997. – Vol. 30. – P. 171–179.
8. Waller B. F., Palumbo P. J., Lie J. T., Roberts W. C. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects // Amer. J. Med. – 1980. – Vol. 69. – P. 498–506.
9. Lemp G. F., Vander Zwaag R., Hughes J. P. et al. Association between the severity of diabetes mellitus and coronary arterial atherosclerosis // Amer. J. Cardiol. – 1987. – Vol. 60. – P. 1015–1019.
10. Ledru F., Ducimetiere P., Battaglia S. et al. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study // J. Amer. Coll. Cardiol. – 2001. – Vol. 37. – P. 1543–1550.
11. Burchfiel C. M., Reed D. M., Marcus E. B. et al. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions: an autopsy study from the Honolulu Heart Program // Amer. J. Epidemiol. – 1993. – Vol. 137. – P. 1328–1340.
12. Goraya T. Y., Leibson C. L., Palumbo P. J. et al. Coronary atherosclerosis in diabetes mellitus: a populationbased autopsy study // J. Amer. Coll. Cardiol. – 2002. – Vol. 40. – P. 946–953.
13. Woodfield S. L., Lundergan C. F., Reiner J. S. et al; GUSTO-I Angiographic Investigators. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience // Ibid. – 1996. – Vol. 28. – P. 1661–1669.
14. Mak K. H., Faxon D. P. Clinical studies on coronary revascularization in patients with type 2 diabetes // Eur. Heart J. – 2003. – Vol. 24. – P. 1087–1103.
15. Moreno P. R., Murcia A. M., Palacios I. F. et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus // Circulation. – 2000. – Vol. 102. – P. 2180–2184.
16. Hermiller J. B., Tenaglia A. N., Kisslo K. B. et al. In vivo validation of compensatory enlargement of atherosclerotic coronary arteries // Amer. J. Cardiol. – 1993. – Vol. 71. – P. 665–668.
17. Vavuranakis M., Stefanadis C., Toutouzas K. et al. Impaired compensatory coronary artery enlargement in atherosclerosis contributes to the development of coronary artery stenosis in diabetic patients: an in vivo intravascular ultrasound study // Eur. Heart J. – 1997. – Vol. 18. – P. 1090–1094.
18. Abaci A., Oguzhan A., Kahraman S. et al. Effect of diabetes mellitus on formation of coronary collateral vessels // Circulation. – 1999. – Vol. 99. – P. 2239–2242.
19. Nesto R. W. Correlation between cardiovascular disease and diabetes mellitus: current concepts // Amer. J. Med. – 2004. – Vol. 116 (Suppl. 5A). – P. 11S–22S.
20. Stratton L., Adler А., Neil Н. et al. Association of glycaemia with macrovascular and microvascular comp1ications of type 2 diabetes (UKPDS 35): prospective observational study // Brit. Med. J. – 2000. – Vol. 321. – Р. 405–412.
21. Guerci B., Bohme P., Kearney-Schwartz A. et al. Endothelial dysfunction and type 2 diabetes // Diabetes Metab. – 2001. – Vol. 27. – P. 436–447.
22. Verma S., Maitland A., Weisel R. D. et al. Hyperglycemia exaggerates ischemia-reperfusioninduced cardiomyocyte injury: reversal with endothelin antagonism // J. Thorac. Cardiovasc. Surg. – 2002. – Vol. 123. – P. 1120–1124.
23. Fontbonne A. M., Eschwe` ge E. M. Insulin and cardiovascular disease. Paris Prospective Study // Diabetes Care. – 1991. – Vol. 14, № 6. – P. 461–469.
24. Fournier A. M., Gadia M. T., Kubrusly D. B. et al. Blood pressure, insulin, and glycemia in nondiabetic subjects // Amer. J. Med. – 1986. – Vol. 80. – P. 861–864.
25. Stout R. W. Insulin and atheroma – an update // Lancet. – 1987. – Vol. 9, № 8541. – P. 1077–1079.
26. Steiner G. The dyslipoproteinemias of diabetes // Atherosclerosis. – 1994. – Vol. 110 (Suppl.). – P. 27–33.
27. Taskinen M. R. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus // Diabetes.– 1992. – Vol. 41 (Suppl. 2). – P. 12–17.
28. Abdella N., Mosimineyi O., Moussa M. Case control study of C-reactive protein with coronary heart disease in patients with type 2 diabetes mellitus // Ibid. – 2002. – Vol. 51 (Suppl. 2). – P. 1165–1166.
29. Hotamisligil G. S., Arner P., Caro J. F. Increased adipose tissue expression of tumor necrosis factor in human obesity and insulin resistance // J. Clin. Invest. – 1995. – Vol. 95. – P. 2409–2415.
30. Davi G., Catalan I., Averna M. Thromboxane biosynthesis and platelet function in type II diabetes mellitus // N. Engl J. Med. – 1990. – Vol. 322. – P. 1769–1774.
31. Marfella R., Esposito K., Gionta R. et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia // Circulation. – 2000. – Vol. 101. – P. 2247–2251.
32. Creager M. A., Luscher T. F., Cosentino F., Beckman J. A. Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: part I // Circulation. – 2003. – Vol. 108. – P. 1527–1532.
33. Henderson R. A., Pocock S. J., Sharp S. J. et al; Randomised Intervention Treatment of Angina. Longterm results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary- artery bypass grafting // Lancet. – 1998. – Vol. 352. – P. 1419–1425.
34. King S. B., Kosinski A. S., Guyton R. A. et al.; EAST Investigators. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) // J. Amer. Coll. Cardiol. – 2000. – Vol. 35. – P. 1116–1121.
35. Kurbaan A. S., Bowker T. J., Ilsley C. D. et al.; CABRI Investigators. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode // Amer. J. Cardiol. – 2001. – Vol. 87. – P. 947–950.
36. Bypass Angioplasy Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease // N. Engl. J. Med. – 1996. – Vol. 335. – P. 217–225.
37. Bypass Angioplasy Revascularization Investigation (BARI) Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status // J. Amer. Coll. Cardiol. – 2000. – Vol. 35. – P. 1122–1129.
38. Abizaid A., Costa M. A., Centemero M. et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial // Circulation. – 2001. – Vol. 104. – P. 533–538.
39. Legrand V. M., Serruys P. W., Unger F. et al. Threeyear outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease // Ibid. – 2004. – Vol. 109. – P. 1114–1120.
40. Sedlis S. P., Morrison D. A., Lorin J. D. et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry // J. Amer. Coll. Cardiol. – 2002. – Vol. 40. – P. 1555–1566.
41. Macaya C., Garcia H., Serruys P. W. et al. Sirolimus-eluting stent versus surgery and bare metal stenting in the treatment of diabetic patients with multivessel disease–a comparison between ARTS II and ARTS I // Circulation. – 2005. – Vol. 112 (Suppl. II). – P. II–655.
42. Bhatt D. L., Marso S. P., Lincoff M. et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2000. – Vol. 35. – P. 922–928.
43. Hong S. J., Kim M. H., Ahn Y. K. et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes // Heart. – 2006. – Vol. 92. – P. 1119–1124.
44. Kornowski R., Mintz G. S., Kent K. M. et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study // Circulation. – 1997. – Vol. 95. – P. 1366–1369.
45. Carrozza J. P. Jr., Kuntz R. E., Fishman R. F., Baim D. S. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus // Ann. Intern. Med. – 1993. – Vol. 118. – P. 344–349.
46. Corpus R. A., George P. B., House J. A. et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2004. – Vol. 43. – P. 8–14.
47. Moses J. W., Leon M. B., Popma J. J. et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery // N. Engl. J. Med. – 2003. – Vol. 349. – P. 1315–1323.
48. Holmes D. R., Leon M. B., Moses J. W. et al.; SIRIUS Investigators. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimuseluting stent versus a standard stent in patients at high risk for coronary restenosis // Circulation. – 2004. – Vol. 109. – P. 634–640.
49. Moussa I., Leon M. B., Baim D. S. Impact of sirolimuseluting stents on outcome in diabetic patients: a SIRIUS (Sirolimus-Coated Bx Velocity Balloon- Expandable Stent in the Treatment of Patients With de novo Coronary Artery Lesions) substudy // Ibid. – 2004. – Vol. 109. – P. 2273–2278.
50. Stone G. W., Ellis S. G., Cox D. A. et al.; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease // N. Engl. J. Med. – 2004. – Vol. 350. – P. 221–231.
51. Stone G. W., Ellis S. G., Cox D. A. et al.; TAXUS-IV Investigators. One-year clinical results with the slowrelease, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial // Circulation. – 2004. – Vol. 109. – P. 1942–1947.
52. Stone G. W. The pivotal, prospective trial of the slow-rate release polymer-based paclitaxel-eluting taxus stent in patients with de novo coronary lesions: 2-year clinical results of the TAXUS-IV trial. Presented at: Transcatheter Cardiovascular Therapeutics (TCT); September 27–October 1, 2004; Washington, DC. Available at: http://www.tctmd.com.
53. Sabaté M., Jimenez-Quevedo P., Angiolillo D. J. et al. DIABETES Investigators. Diabetes and sirolimus eluting stent trial: the DIABETES trial. Presented at Transcatheter Cardiovascular Therapeutics (TCT); September 27–October 1, 2004; Washington, DC. Available at: http://www.tctmd.com. Accessed November 1, 2004.
54. Furnary A. P., Gao G., Grunkemeier G. L. et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting // J. Thorac. Cardiovasc. Surg. – 2003. – Vol. 125. – P. 1007–1021.
55. Svensson S., Svedjeholm R., Ekroth R. Trauma metabolism of the heart: uptake of substrates and effects of insulin early after cardiac operations // Ibid. – 1990. – Vol. 99. – P. 1063–1073.
56. Dandona P., Aljada A., Mohanty P. et al. Insulin inhibits intranuclear nuclear factor kB and stimulates kB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect // J. Clin. Endocrinol. Metab. – 2001. – Vol. 86. – P. 3257–3265.
57. Lazar H. L., Chipkin S. R., Fitzgerald C. A. et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events // Circulation. – 2004. – Vol. 109. – P. 1497–1502.
58. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // Lancet. – 2000. – Vol. 355. – P. 253–259.
59. Collins R., Armitage J., Parish S. et al. HPS Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebocontrolled trial // Lancet. – 2003. – Vol. 361. – P. 2005–2016.
60. Colhoun H. M., Betteridge D. J., Durrington P. N. et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled trial // Lancet. – 2004. – Vol. 364. – P. 685–696.
61. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. – 2002. – Vol. 324. – P. 71–86.
62. Jonas M., Reicher-Reiss H., Boyko V. et al.; Bezafibrate Infarction Prevention (BIP) Study Group. Usefulness of beta-blocker therapy in patients with noninsulin – dependent diabetes mellitus and coronary artery disease // Amer. J. Cardiol. – 1996. – Vol. 77. – P. 1273–1277.
63. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery) Kim A. Eagle, Robert A. Guyton et al. (www.acc.org).
64. ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing Committee to Update the 2001 Guidelines for percutaneous coronary intervention). Sidney C. Smith, Ted E. Feldman et al. // JACC. – 2006. – Vol. 47. – P. 1–121.
65. Lars Rydern, Eberhard Standl, Margorzata Bartnik et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) // Eur. Heart J. – 2007. – Vol. 28. – P. 88–136 (doi:10.1093/eurheartj/ehl260).
References
1. Smith S. C., Jr., Dove J. T., Jacobs A. K. et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) // J. Amer. Coll. Cardiol. – 2001. – Vol. 37. – P. 2215–2239.2. Gruеntzig A. R., Senning A., Siegenthaler W. E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty // N. Engl. J. Med. – 1979. – Vol. 301. – P. 61–68.
3. Hammound T., Tanguay J. F., Bourassa M. G. Management of coronary artery disease: therapeutic options in patients with diabetes // J. Amer. Coll. Cardiol. – 2000. – Vol. 36. – P. 355–365.
4. King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995 – 2025: prevalence, numerical estimates, and projections // Diabetes Care. – 1998. – Vol. 21. – P. 1414–1431.
5. Smith S. C., Faxon D., Cascio W. et al. Diabetes and cardiovascular disease writing group VI: revascularization in diabetic patients // Circulation. – 2002. – Vol. 105. – P. e165–e169.
6. Flaherty James D., Davidson Charles J. Diabetes and Coronary Revascularization // JAMA. – 2005. – Vol. 293. – P. 1501–1508.
7. Mak K. H., Moliterno D. J., Granger C. B. et al. GUSTO-I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction // J. Amer. Coll. Cardiol. – 1997. – Vol. 30. – P. 171–179.
8. Waller B. F., Palumbo P. J., Lie J. T., Roberts W. C. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects // Amer. J. Med. – 1980. – Vol. 69. – P. 498–506.
9. Lemp G. F., Vander Zwaag R., Hughes J. P. et al. Association between the severity of diabetes mellitus and coronary arterial atherosclerosis // Amer. J. Cardiol. – 1987. – Vol. 60. – P. 1015–1019.
10. Ledru F., Ducimetiere P., Battaglia S. et al. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study // J. Amer. Coll. Cardiol. – 2001. – Vol. 37. – P. 1543–1550.
11. Burchfiel C. M., Reed D. M., Marcus E. B. et al. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions: an autopsy study from the Honolulu Heart Program // Amer. J. Epidemiol. – 1993. – Vol. 137. – P. 1328–1340.
12. Goraya T. Y., Leibson C. L., Palumbo P. J. et al. Coronary atherosclerosis in diabetes mellitus: a populationbased autopsy study // J. Amer. Coll. Cardiol. – 2002. – Vol. 40. – P. 946–953.
13. Woodfield S. L., Lundergan C. F., Reiner J. S. et al; GUSTO-I Angiographic Investigators. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience // Ibid. – 1996. – Vol. 28. – P. 1661–1669.
14. Mak K. H., Faxon D. P. Clinical studies on coronary revascularization in patients with type 2 diabetes // Eur. Heart J. – 2003. – Vol. 24. – P. 1087–1103.
15. Moreno P. R., Murcia A. M., Palacios I. F. et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus // Circulation. – 2000. – Vol. 102. – P. 2180–2184.
16. Hermiller J. B., Tenaglia A. N., Kisslo K. B. et al. In vivo validation of compensatory enlargement of atherosclerotic coronary arteries // Amer. J. Cardiol. – 1993. – Vol. 71. – P. 665–668.
17. Vavuranakis M., Stefanadis C., Toutouzas K. et al. Impaired compensatory coronary artery enlargement in atherosclerosis contributes to the development of coronary artery stenosis in diabetic patients: an in vivo intravascular ultrasound study // Eur. Heart J. – 1997. – Vol. 18. – P. 1090–1094.
18. Abaci A., Oguzhan A., Kahraman S. et al. Effect of diabetes mellitus on formation of coronary collateral vessels // Circulation. – 1999. – Vol. 99. – P. 2239–2242.
19. Nesto R. W. Correlation between cardiovascular disease and diabetes mellitus: current concepts // Amer. J. Med. – 2004. – Vol. 116 (Suppl. 5A). – P. 11S–22S.
20. Stratton L., Adler А., Neil Н. et al. Association of glycaemia with macrovascular and microvascular comp1ications of type 2 diabetes (UKPDS 35): prospective observational study // Brit. Med. J. – 2000. – Vol. 321. – Р. 405–412.
21. Guerci B., Bohme P., Kearney-Schwartz A. et al. Endothelial dysfunction and type 2 diabetes // Diabetes Metab. – 2001. – Vol. 27. – P. 436–447.
22. Verma S., Maitland A., Weisel R. D. et al. Hyperglycemia exaggerates ischemia-reperfusioninduced cardiomyocyte injury: reversal with endothelin antagonism // J. Thorac. Cardiovasc. Surg. – 2002. – Vol. 123. – P. 1120–1124.
23. Fontbonne A. M., Eschwe` ge E. M. Insulin and cardiovascular disease. Paris Prospective Study // Diabetes Care. – 1991. – Vol. 14, № 6. – P. 461–469.
24. Fournier A. M., Gadia M. T., Kubrusly D. B. et al. Blood pressure, insulin, and glycemia in nondiabetic subjects // Amer. J. Med. – 1986. – Vol. 80. – P. 861–864.
25. Stout R. W. Insulin and atheroma – an update // Lancet. – 1987. – Vol. 9, № 8541. – P. 1077–1079.
26. Steiner G. The dyslipoproteinemias of diabetes // Atherosclerosis. – 1994. – Vol. 110 (Suppl.). – P. 27–33.
27. Taskinen M. R. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus // Diabetes.– 1992. – Vol. 41 (Suppl. 2). – P. 12–17.
28. Abdella N., Mosimineyi O., Moussa M. Case control study of C-reactive protein with coronary heart disease in patients with type 2 diabetes mellitus // Ibid. – 2002. – Vol. 51 (Suppl. 2). – P. 1165–1166.
29. Hotamisligil G. S., Arner P., Caro J. F. Increased adipose tissue expression of tumor necrosis factor in human obesity and insulin resistance // J. Clin. Invest. – 1995. – Vol. 95. – P. 2409–2415.
30. Davi G., Catalan I., Averna M. Thromboxane biosynthesis and platelet function in type II diabetes mellitus // N. Engl J. Med. – 1990. – Vol. 322. – P. 1769–1774.
31. Marfella R., Esposito K., Gionta R. et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia // Circulation. – 2000. – Vol. 101. – P. 2247–2251.
32. Creager M. A., Luscher T. F., Cosentino F., Beckman J. A. Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: part I // Circulation. – 2003. – Vol. 108. – P. 1527–1532.
33. Henderson R. A., Pocock S. J., Sharp S. J. et al; Randomised Intervention Treatment of Angina. Longterm results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary- artery bypass grafting // Lancet. – 1998. – Vol. 352. – P. 1419–1425.
34. King S. B., Kosinski A. S., Guyton R. A. et al.; EAST Investigators. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) // J. Amer. Coll. Cardiol. – 2000. – Vol. 35. – P. 1116–1121.
35. Kurbaan A. S., Bowker T. J., Ilsley C. D. et al.; CABRI Investigators. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode // Amer. J. Cardiol. – 2001. – Vol. 87. – P. 947–950.
36. Bypass Angioplasy Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease // N. Engl. J. Med. – 1996. – Vol. 335. – P. 217–225.
37. Bypass Angioplasy Revascularization Investigation (BARI) Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status // J. Amer. Coll. Cardiol. – 2000. – Vol. 35. – P. 1122–1129.
38. Abizaid A., Costa M. A., Centemero M. et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial // Circulation. – 2001. – Vol. 104. – P. 533–538.
39. Legrand V. M., Serruys P. W., Unger F. et al. Threeyear outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease // Ibid. – 2004. – Vol. 109. – P. 1114–1120.
40. Sedlis S. P., Morrison D. A., Lorin J. D. et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry // J. Amer. Coll. Cardiol. – 2002. – Vol. 40. – P. 1555–1566.
41. Macaya C., Garcia H., Serruys P. W. et al. Sirolimus-eluting stent versus surgery and bare metal stenting in the treatment of diabetic patients with multivessel disease–a comparison between ARTS II and ARTS I // Circulation. – 2005. – Vol. 112 (Suppl. II). – P. II–655.
42. Bhatt D. L., Marso S. P., Lincoff M. et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2000. – Vol. 35. – P. 922–928.
43. Hong S. J., Kim M. H., Ahn Y. K. et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes // Heart. – 2006. – Vol. 92. – P. 1119–1124.
44. Kornowski R., Mintz G. S., Kent K. M. et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study // Circulation. – 1997. – Vol. 95. – P. 1366–1369.
45. Carrozza J. P. Jr., Kuntz R. E., Fishman R. F., Baim D. S. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus // Ann. Intern. Med. – 1993. – Vol. 118. – P. 344–349.
46. Corpus R. A., George P. B., House J. A. et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2004. – Vol. 43. – P. 8–14.
47. Moses J. W., Leon M. B., Popma J. J. et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery // N. Engl. J. Med. – 2003. – Vol. 349. – P. 1315–1323.
48. Holmes D. R., Leon M. B., Moses J. W. et al.; SIRIUS Investigators. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimuseluting stent versus a standard stent in patients at high risk for coronary restenosis // Circulation. – 2004. – Vol. 109. – P. 634–640.
49. Moussa I., Leon M. B., Baim D. S. Impact of sirolimuseluting stents on outcome in diabetic patients: a SIRIUS (Sirolimus-Coated Bx Velocity Balloon- Expandable Stent in the Treatment of Patients With de novo Coronary Artery Lesions) substudy // Ibid. – 2004. – Vol. 109. – P. 2273–2278.
50. Stone G. W., Ellis S. G., Cox D. A. et al.; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease // N. Engl. J. Med. – 2004. – Vol. 350. – P. 221–231.
51. Stone G. W., Ellis S. G., Cox D. A. et al.; TAXUS-IV Investigators. One-year clinical results with the slowrelease, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial // Circulation. – 2004. – Vol. 109. – P. 1942–1947.
52. Stone G. W. The pivotal, prospective trial of the slow-rate release polymer-based paclitaxel-eluting taxus stent in patients with de novo coronary lesions: 2-year clinical results of the TAXUS-IV trial. Presented at: Transcatheter Cardiovascular Therapeutics (TCT); September 27–October 1, 2004; Washington, DC. Available at: http://www.tctmd.com.
53. Sabaté M., Jimenez-Quevedo P., Angiolillo D. J. et al. DIABETES Investigators. Diabetes and sirolimus eluting stent trial: the DIABETES trial. Presented at Transcatheter Cardiovascular Therapeutics (TCT); September 27–October 1, 2004; Washington, DC. Available at: http://www.tctmd.com. Accessed November 1, 2004.
54. Furnary A. P., Gao G., Grunkemeier G. L. et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting // J. Thorac. Cardiovasc. Surg. – 2003. – Vol. 125. – P. 1007–1021.
55. Svensson S., Svedjeholm R., Ekroth R. Trauma metabolism of the heart: uptake of substrates and effects of insulin early after cardiac operations // Ibid. – 1990. – Vol. 99. – P. 1063–1073.
56. Dandona P., Aljada A., Mohanty P. et al. Insulin inhibits intranuclear nuclear factor kB and stimulates kB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect // J. Clin. Endocrinol. Metab. – 2001. – Vol. 86. – P. 3257–3265.
57. Lazar H. L., Chipkin S. R., Fitzgerald C. A. et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events // Circulation. – 2004. – Vol. 109. – P. 1497–1502.
58. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // Lancet. – 2000. – Vol. 355. – P. 253–259.
59. Collins R., Armitage J., Parish S. et al. HPS Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebocontrolled trial // Lancet. – 2003. – Vol. 361. – P. 2005–2016.
60. Colhoun H. M., Betteridge D. J., Durrington P. N. et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled trial // Lancet. – 2004. – Vol. 364. – P. 685–696.
61. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. – 2002. – Vol. 324. – P. 71–86.
62. Jonas M., Reicher-Reiss H., Boyko V. et al.; Bezafibrate Infarction Prevention (BIP) Study Group. Usefulness of beta-blocker therapy in patients with noninsulin – dependent diabetes mellitus and coronary artery disease // Amer. J. Cardiol. – 1996. – Vol. 77. – P. 1273–1277.
63. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery) Kim A. Eagle, Robert A. Guyton et al. (www.acc.org).
64. ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing Committee to Update the 2001 Guidelines for percutaneous coronary intervention). Sidney C. Smith, Ted E. Feldman et al. // JACC. – 2006. – Vol. 47. – P. 1–121.
65. Lars Rydern, Eberhard Standl, Margorzata Bartnik et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) // Eur. Heart J. – 2007. – Vol. 28. – P. 88–136 (doi:10.1093/eurheartj/ehl260).
